Bethesda, MD, July 11, 2013: The Association for Molecular Pathology (AMP) submitted comments to the Centers for Medicare and Medicaid Services (CMS) expressing serious concerns about the gap fill process. "Overall, the process neglects to take into account the unique and valuable expertise of the professionals who interpret the data," said AMP President, Jennifer L. Hunt, MD, MEd, "Acknowledgement of the time, resources, and risk assumed by the specially trained individuals who analyze the complex datasets is absent from the current structure. It is those physicians and doctoral scientists who are legally responsible for the accuracy of the results."
AMP's comments point out that since the new codes took effect on January 1, 2013, many laboratories have gone without reimbursement for their services. This lack of coverage is a result of payment amounts that have not yet been determined as well as those in which the cost exceeds the reimbursement amount. "The current payment standard is unsustainable," said Jan A. Nowak, MD, PhD, Co-Chair of the AMP Economic Affairs Committee (EAC). "Labs are being forced to either discontinue critical tests or endure significant revenue shortages due to lack of coverage under the existing policies." With laboratories unable to perform certain tests, it is ultimately the patient who suffers.
The absence of transparency within the gap fill process is another significant issue raised by AMP in their comments. Alternative solutions exist that are supported by AMP and other professional societies. These solutions offer the transparency, data collection procedures, payment structures, and the flexibility to adapt as needed based on public input. One solution would have been placement of the new molecular pathology CPT codes on the Physician Fee Schedule (PFS). "Significant effort was spent in determining the practice expense and professional work involved for most of the codes," said Aaron D. Bossler, MD, PhD, C
|Contact: Catherine Davidge|
Association for Molecular Pathology